BAYERN JOSEPH sold $3K of CGC

BAYERN JOSEPH sold 3,096 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-28.

Original reporting
SEC EDGAR · BAYERN JOSEPH
Published Sep 30, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The transaction is small relative to total holdings, suggesting limited market impact.

02

Market read

A modest insider sell with low trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing by the director.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Director Bayern Joseph sold 3,096 shares of Canopy Growth Corp for $2,869, a primary Form 4 filing.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

The sale is modest in size relative to holdings and does not represent a material change.

Market effects

Minimal impact on the cannabis sector; insider sales are routine.

No broader regional effect.

Limited to investors tracking CGC.

Counterpoint

The sale could be unrelated to fundamentals and may not affect price.

Key entities

  • Canopy Growth Corp

    US‑listed cannabis producer (ticker CGC).

  • Bayern Joseph

    Director of Canopy Growth Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.